A Double-Blind, Controlled Study to Compare the Gastrointestinal Safety of a 14-Day Oral Dosing Regimen of ATB-346 to Sodium Naproxen in Healthy Subjects

Trial Profile

A Double-Blind, Controlled Study to Compare the Gastrointestinal Safety of a 14-Day Oral Dosing Regimen of ATB-346 to Sodium Naproxen in Healthy Subjects

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs ATB 346 (Primary) ; Naproxen
  • Indications Intestinal cancer; Malignant melanoma; Pain; Periodontal disorders
  • Focus Adverse reactions; Proof of concept
  • Sponsors Antibe Therapeutics
  • Most Recent Events

    • 08 Sep 2017 According to an Antibe Therapeutics media release, the company announced that the first eight subjects have been enrolled and are on treatment in this trial.
    • 08 Sep 2017 Status changed from planning to recruiting, according to an Antibe Therapeutics media release.
    • 29 Aug 2017 According to the Antibe Therapeutics media release, a data from this trial is anticipated in Q1 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top